GPC3 and neoplasm: Notable investigational agents include the following: RAYZ-8009 (DOTA-RYZ-GPC3), targeting glypican-3 in hepatocellular carcinoma [60], and 177Lu-FAP-2286, directed against fibroblast activation protein (FAP) in stromal-rich tumours [62].